Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Varian (VAR) Scales New 52-Week High on Solid Prospects

by Zacks Equity Research

The key growth driving factor for Varian (VAR) in the past year has been increasing net sales from major business segments.

Baxter (BAX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results

by Zacks Equity Research

The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.

Edwards Lifesciences Presents Positive Partner 3 Trial Data

by Zacks Equity Research

Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.

Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (revised)

by Zacks Equity Research

The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).

Medtronic (MDT) Releases Encouraging Evalut TAVR Result

by Zacks Equity Research

Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.

Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms

by Zacks Equity Research

Abbott's (ABT) EPD business operates in emerging geographies like India, Russia, China and Latin America.

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised)

by Zacks Equity Research

The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional MR.

What Makes Abbott (ABT) a New Buy Stock

by Zacks Equity Research

Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results

by Zacks Equity Research

The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $78.83, moving -1.29% from the previous trading session.

Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip

by Zacks Equity Research

The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day.

The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

Mark Vickery headshot

Top Analyst Reports for Boeing, Abbott & PayPal

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Abbott (ABT) and PayPal (PYPL).

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.

DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

Here's Why You Should Buy Varian Medical (VAR) Stock Now

by Zacks Equity Research

Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.

Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

by Zacks Equity Research

Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.

Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

by Zacks Equity Research

Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.

Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.

Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts

by Zacks Equity Research

Bruker's (BRKR) CALID and NANO groups hold promise.

Here's Why Investors Should Buy DexCom (DXCM) Stock Now

by Zacks Equity Research

Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.